CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
clonidine +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00349921
NCT00349921Phase 2Completed
CompareCT.gov

Clonidine Versus Adenosine to Treat Neuropathic Pain

Wake Forest University Health Sciences·interventional·Posted Jul 10, 2006·Updated Sep 10, 2018

In Brief

A Phase 2 clinical trial evaluating clonidine, adenosine, and 1 other intervention for Pain. Completed, enrolled 24 participants across 2 sites.

Detailed Summary

The purpose of this study is to determine the effects of clonidine and adenosine on nerve pain.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain
CountriesUnited States
CollaboratorsNational Institute of Neurological Disorders and Stroke (NINDS)

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 10, 2006
Enrollment StartAug 1, 2004
Primary CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 20.0 years ago

Interventions

clonidinedrug

Clonidine-a drug commonly used to treat high blood pressure-has been shown to effectively treat neuropathic pain, is FDA-approved for administration via epidural (an injection given in the lower back), and is the third most commonly prescribed drug for chronic intrathecal (an injection into the cerebrospinal fluid) use in people with chronic pain.

adenosinedrug

Adenosine-a drug commonly administered intravenously (into a vein) to treat certain types of abnormal heart rhythms-has been found to reduce areas of allodynia (pain caused by a stimulus that does not normally cause pain) after intrathecal, but not intravenous administration in people with neuropathic pain.

placebodrug

inactive substance

placebodrug

inactive substance